NattoPharma’s MenaQ7 brand Vitamin K2 standardized to MK-7 content.
Daily intake of 180 micrograms of MenaQ7 may help prevent bone loss and improve bone impact strength in postmenopausal women, delaying development of osteoporosis.
Osteoporosis International as an Online First Article (DOI 10.1007/s00198-013-2325-6).
NattoPharma’s MenaQ7 brand Vitamin K2 provides natural vitamin K2 as a manufactured fermentation extract, generating a highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7).
Methods: In total 244 women were included in the three-year study and randomly assigned to either a non-treatment group receiving placebo capsules (n=124) or a treatment group receiving capsules containing 180 mcg MenaQ7 (n=120). One capsule was taken daily during a period of 36 months. Participants came to the research site every year (0, 1, 2 and 3 years) for measurements of body weight and height, blood sampling and DXA measurements. Compliance was 91.4 percent of the randomized participants staying in the study until its completion.
Results: The MenaQ7 supplementation group significantly increased the circulating active Osteocalcin (cOC), a well-established biomarker for bone- and vitamin K status. The inactive protein, ucOC, in the MenaQ7 group, decreased with 51% +/- 21 % as compared to the placebo group (+4 % +/- 49%). After three years of supplementation, improvements in both bone mineral content (BMC) and bone mineral density (BMD) were statistically significant in the MenaQ7 group. Moreover bone strength (BS) was statistically improved, demonstrating therapeutic benefits for the MenaQ7 group as compared to the placebo group.
Cell: +47 97 53 53 26
E-mail: [email protected]
High-concentration full-spectrum Ashwagandha-root extract (KSM-66®).
The findings suggest that a high-concentration full-spectrum Ashwagandha-root extract safely and effectively improves an individual’s resistance towards stress and thereby improves self-assessed quality of life.
Indian J Psychol Med.2012 Jul;34(3):255-62. doi: 10.4103/0253-7176.106022.
The herb ashwagandha (Withania somnifera Dunal)is a safe and effective adaptogen, as described by Ayurvedic classical texts, animal studies and clinical studies. Adaptogens help in combating stress.
Methods:In this single center, prospective, double-blind, randomized, placebo-controlled trial 64 subjects with a history of chronic stress were enrolled after performing relevant clinical examinations and laboratory tests. These included a measurement of serum cortisol, and assessing their scores on standard stress-assessment questionnaires (t-test, and Mann-Whitney test). They were randomized to either the placebo control group or the study drug treatment group. Subjects were asked to take one capsule (300 mg) of high-concentration full-spectrum extract from the root of the Ashwagandha plant twice a day for a period of 60 days. During the treatment period (on Day 15, Day 30 and Day 45), a follow-up telephone call was made to all subjects to check for treatment compliance and to note any adverse reactions. Final safety and efficacy assessments were done on Day 60.
Results: The treatment group that was given the high-concentration full-spectrum Ashwagandha root extract exhibited a significant reduction (P<0.0001) in scores on all the stress-assessment scales on Day 60, relative to the placebo group. Serum cortisol levels were substantially reduced (P=0.0006) in the Ashwagandha group, relative to the placebo group. The adverse effects were mild in nature and were comparable in both the groups. No serious adverse events were reported.
Ixoreal Biomed Private Ltd.
10849 Weyburn Avenue, Los Angeles, California 90024.